English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The pharmacokinetics and toxicity of once-daily intravenous tobramycin were studied prospectively in seven children with cystic fibrosis. Mean 1 h post-dose concentrations of 21.9 mg/L (S.D. 3.0) and 40.2 mg/L (S.D. 8.1) were achieved following tobramycin doses of 8 mg/kg and 15 mg/kg, respectively. The half-life (mean 2.3 h) was unchanged at the two doses, as were the total clearance and volume of distribution. All patients responded well to therapy. No nephrotoxicity occurred, but one patient showed transient ototoxicity.

The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis